Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider BioMarin Pharmaceutical (BMRN) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.This rare disease biopharmaceutical has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an avera ...